TrialInvestigational new drugs2019

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Khalid Jazieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.